Merck announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP, adopted an opinion recommending approval of Keytruda, Merck’s anti-PD-1 therapy, for the adjuvant treatment of adults with non-small cell lung cancer, or NSCLC, who are at high risk of recurrence following complete resection and platinum-based chemotherapy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRK:
- VTI ETF: This Diversified Powerhouse Owns Over 3,800 Stocks
- FDA approves new and updated indications for Merck’s temozolomide
- Bionomics provides update on Merck collaboration
- IO Biotech announces data related to IO102-IO103 in combination with KEYTRUDA
- European Commission approves expanded indication for Merck’s ERVEBO